K-Cab Drug Interactions

Drugs dependent on Gastric pH for Absorption: Due to its effects on gastric acid secretion, tegoprazan can reduce the absorption of drugs where gastric pH is an important determinant of their bioavailability. Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, itraconazole, ampicillin ester, atazanavir, iron salts, erlotinib, gefitinib and mycophenolate mofetil (MMF) can decrease during treatment with tegoprazan. While absorption of drugs such as digoxin can increase during treatment with K-CAB. Because tegoprazan inhibits gastric acid secretion, co-administration of atazanavir, nelfinavir and rilpivirin with tegoprazan is expected to decrease plasma concentration of atazanavir, nelfinavir or rilpivirin which is dependent on gastric pH for absorption, results in a loss of the therapeutic effect. Therefore, concomitant use of atazanavir, nelfinavir and rilpivirine with K-CAB is contraindicated.
Tegoprazan is mainly metabolized by CYP3A4. Concomitant use of clarithromycin, a CYP3A4 inhibitor, with tegoprazan has increased AUCτ of tegoprazan and clarithromycin by 2.5 times and 1.25 times, respectively.
Tegoprazan has been shown to have no clinically significant effects on the pharmacokinetics of amoxicillin.